ACOG
Neutral signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Unavailable or mixed. Current ratio 8.65 · operating margin -222% — readings disagree
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 10000 titres (~96200 USD)
- Insiders
- Wills Robert James
- Total bought
-
$96,200
Avg buy (VWAP, 90d window) $9.62 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-08-21
- Last synced
-
2026-08-25 17:08:49
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-21 | Wills Robert James | Buy | 10,000 | $9.62 | $96,200 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Neutral signalScored 2026-08-27
ACOG presents a meaningful catalyst signal with insider buying following a strong Q2 revenue beat (+71% sequential) and a European patent grant for ZUNVEYL, but the deeply deteriorated fundamentals (EBIT margin of…
The first sentence of the analysis written for ACOG on 2026-08-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 81.3% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | -221.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | -221.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | -221.7% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | -202.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | -202.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | -202.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | -202.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 8.654 | 14.997 | 0.731 | 0.575 | 6.751 | |
| Quick Ratio | 8.093 | 14.813 | 0.731 | 0.575 | 6.751 | |
| Solvency Ratio | -1.198 | -1.570 | -1.910 | -2.815 | -5.052 | |
| Cash Ratio | 7.240 | 14.488 | 0.569 | 0.514 | 6.269 | |
| Price To Earnings Ratio | -5.556 | -2.916 | -1.849 | -1.589 | -0.761 | |
| Price To Earnings Growth Ratio | 0.132 | 0.062 | 0.051 | 0.033 | -0.003 | |
| Forward Price To Earnings Growth Ratio | 0.132 | 0.062 | 0.051 | 0.033 | -0.003 | |
| Price To Earnings Diluted Ratio | -5.556 | -2.916 | -1.849 | -1.589 | -0.761 | |
| Price To Earnings Diluted Growth Ratio | 0.132 | 0.062 | 0.051 | 0.033 | -0.003 | |
| Price To Book Ratio | 1.838 | 1.030 | -5.402 | -14.737 | 1.664 | |
| Price To Sales Ratio | 11.245 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -5.559 | -5.485 | -2.916 | -2.104 | -1.511 | |
| Price To Operating Cash Flow Ratio | -5.639 | -5.504 | -2.916 | -2.105 | -1.521 | |
| Debt To Assets Ratio | 0.000 | 0.018 | 0.498 | 0.411 | 0.084 | |
| Debt To Equity Ratio | 0.000 | 0.022 | -0.259 | -0.918 | 0.119 | |
| Debt To Capital Ratio | 0.000 | 0.022 | -0.349 | -11.144 | 0.106 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.275 | 1.224 | -0.520 | -2.235 | 1.426 | |
| Working Capital Turnover Ratio | 0.175 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.232 | -2.315 | -3.325 | -2.278 | -5.480 | |
| Operating Cash Flow Sales Ratio | -1.994 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | 1.003 | 1.000 | 1.001 | 1.006 | |
| Debt Service Coverage Ratio | 0.000 | -13.096 | -10.574 | -8.561 | -11.800 | |
| Interest Coverage Ratio | 0.000 | -63.844 | -142.040 | -77.890 | -21.904 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -8.509 | -7.153 | -7.629 | -9.183 | |
| Operating Cash Flow Coverage Ratio | 0.000 | -8.509 | -7.153 | -7.629 | -9.183 | |
| Capital Expenditure Coverage Ratio | -69.442 | -290.463 | -1,745,758.829 | -1,895.335 | -155.174 | |
| Dividend Paid And Capex Coverage Ratio | -69.442 | -290.463 | -1,745,758.829 | -1,895.335 | -155.174 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.154 | 0.344 | -1.849 | -1.568 | -0.253 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 81.3% | ▲81.3% | ▲65.0% |
| Ebit Margin | -221.7% | ▼-221.7% | ▼-177.4% |
| Ebitda Margin | -221.7% | ▼-221.7% | ▼-177.4% |
| Operating Profit Margin | -221.7% | ▼-221.7% | ▼-177.4% |
| Pretax Profit Margin | -202.2% | ▼-202.2% | ▼-161.8% |
| Continuous Operations Profit Margin | -202.2% | ▼-202.2% | ▼-161.8% |
| Net Profit Margin | -202.2% | ▼-202.2% | ▼-161.8% |
| Bottom Line Profit Margin | -202.2% | ▼-202.2% | ▼-161.8% |
| Current Ratio | 8.654 | ▼-6.343 | ▲2.312 |
| Quick Ratio | 8.093 | ▼-6.721 | ▲1.900 |
| Solvency Ratio | -1.198 | ▲0.371 | ▲1.311 |
| Cash Ratio | 7.240 | ▼-7.248 | ▲1.424 |
| Price To Earnings Ratio | -5.556 | ▼-2.640 | ▼-3.021 |
| Price To Earnings Growth Ratio | 0.132 | ▲0.070 | ▲0.077 |
| Forward Price To Earnings Growth Ratio | 0.132 | ▲0.070 | ▲0.077 |
| Price To Earnings Diluted Ratio | -5.556 | ▼-2.640 | ▼-3.021 |
| Price To Earnings Diluted Growth Ratio | 0.132 | ▲0.070 | ▲0.077 |
| Price To Book Ratio | 1.838 | ▲0.808 | ▲4.959 |
| Price To Sales Ratio | 11.245 | ▲11.245 | ▲8.996 |
| Price To Free Cash Flow Ratio | -5.559 | ▼-0.073 | ▼-2.044 |
| Price To Operating Cash Flow Ratio | -5.639 | ▼-0.135 | ▼-2.102 |
| Debt To Assets Ratio | 0.000 | ▼-0.018 | ▼-0.202 |
| Debt To Equity Ratio | 0.000 | ▼-0.022 | ▲0.207 |
| Debt To Capital Ratio | 0.000 | ▼-0.021 | ▲2.273 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.275 | ▲0.051 | ▲1.041 |
| Working Capital Turnover Ratio | 0.175 | ▲0.175 | ▲0.140 |
| Operating Cash Flow Ratio | -2.232 | ▲0.082 | ▲0.894 |
| Operating Cash Flow Sales Ratio | -1.994 | ▼-1.994 | ▼-1.595 |
| Free Cash Flow Operating Cash Flow Ratio | 1.014 | ▲0.011 | ▲0.009 |
| Debt Service Coverage Ratio | 0.000 | ▲13.096 | ▲8.806 |
| Interest Coverage Ratio | 0.000 | ▲63.843 | ▲61.136 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲8.509 | ▲6.495 |
| Operating Cash Flow Coverage Ratio | 0.000 | ▲8.509 | ▲6.495 |
| Capital Expenditure Coverage Ratio | -69.442 | ▲221.021 | ▲349564.407 |
| Dividend Paid And Capex Coverage Ratio | -69.442 | ▲221.021 | ▲349564.407 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.154 | ▼-2.498 | ▼-1.058 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $114.9M | $42.7M | $25.5M | $26.1M | $19.1M | |
| Enterprise value | $48.8M | -$4.9M | $25.2M | $25.0M | $6.1M | |
| EV / Sales | 4.78x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -2.40x | 0.64x | -2.88x | -2.01x | -0.49x | |
| EV / Free cash flow | -2.36x | 0.64x | -2.88x | -2.01x | -0.48x | |
| EV / EBITDA | -2.15x | 0.34x | -1.85x | -1.57x | -0.25x | |
| Net debt / EBITDA | 2.92x | 3.31x | 0.02x | 0.07x | 0.54x | |
| Current ratio | 8.65x | 15.00x | 0.73x | 0.57x | 6.75x | |
| Income quality | 0.99x | 0.53x | 0.63x | 0.76x | 0.51x | |
| Graham net-net | $3 | $5 | -$2 | -$1 | $4 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 91.2% | 101.3% | 100.5% | 101.4% | 102.8% | |
| Working capital | $69.9M | $46.9M | -$706K | -$2.3M | $13.2M | |
| Invested capital | $70.6M | $47.3M | -$173K | -$1.5M | $14.1M | |
| Return on assets | -25.9% | -28.8% | -561.6% | -410.5% | -151.7% | |
| Operating ROA | -34.7% | -44.6% | -299.8% | -177.5% | -108.5% | |
| Return on tangible assets | -26.1% | -29.1% | -717.3% | -518.5% | -160.4% | |
| Return on equity | -33.1% | -35.3% | 292.2% | 917.7% | -216.5% | |
| Return on invested capital | -32.1% | -24.6% | -918.0% | -12755.3% | -95.2% | |
| Return on capital employed | -32.1% | -25.0% | 5568.1% | 1217.6% | -104.4% | |
| Earnings yield | -18.0% | -34.3% | -54.1% | -62.3% | -130.1% | |
| Free cash flow yield | -18.0% | -18.2% | -34.3% | -47.5% | -66.2% | |
| Capex / Op. cash flow | -1.4% | -0.3% | -0.0% | -0.1% | -0.6% | |
| Capex / Depreciation | 501.1% | 32.9% | 0.0% | 5.4% | 70.8% | |
| Capex / Sales | 2.9% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 284.5% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 18.3% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 48.2% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.5% | 0.8% | 21.7% | 20.8% | 5.4% | |
| Days sales outstanding | 151d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 585d | 0d | 0d | 0d | 0d | |
| Operating cycle | 1128d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 543d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+169.2%EV / Sales n/aEV / EBITDA ▼-726.1%EV / Op. cash flow ▼-3.033Earnings yield ▲+0.163
Profitability
Return on equity ▲+0.022Return on assets ▲+0.029Return on invested capital ▼-0.075Return on capital employed ▼-0.071Operating ROA ▲+0.099Income quality ▲+0.456Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-6.343Net debt / EBITDA ▼-0.398Working capital ▲+22979771.000Invested capital ▲+23259688.000Intangibles / Total assets ▼-0.003
Change over 5 years
Valuation
Market cap ▲+500.2%EV / Sales n/aEV / EBITDA ▼-750.0%EV / Op. cash flow ▼-1.910Earnings yield ▲+1.121
Profitability
Return on equity ▲+1.834Return on assets ▲+1.258Return on invested capital ▲+0.631Return on capital employed ▲+0.723Operating ROA ▲+0.737Income quality ▲+0.481Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+1.902Net debt / EBITDA ▲+2.377Working capital ▲+56666405.000Invested capital ▲+56481787.000Intangibles / Total assets ▼-0.049
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-17 Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26 Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition''s 2Q26 strengthens the ZUNVEYL launch setup, with results ahead of prior expectations and demand accelerating despite slower payer implementation.
- 2026-08-14 Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
- 2026-08-13 Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.
- 2026-08-13 Alpha Cognition Q2 Earnings Call Highlights Alpha Cognition NASDAQ: ACOG reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer''s treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facilities.
- 2026-08-13 Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a business update. “We are pleased with the continued commercial adoption of ZUNVEYL during the second quarter,” said Michael McFadden, Chief Executive Officer of Alpha.
- 2026-08-06 Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-08-03 Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its second quarter financial results and business highlights on that date. The financial.
- 2026-07-29 Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer''s Disease VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that the European Patent Office (EPO) has granted a patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in the treatment of mild-to-moderate Alzheimer''s disease. The patent includes.
- 2026-07-28 Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains? Alpha Cognition Inc. (ACOG) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn''t suggest further strength down the road.
- 2026-07-23 Playing The Biotech Breakout With Insiders Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL''s Phase 2 efficacy readout for ABCL635 in Q3 and ACOG''s Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.